Walgreens Boots Alliance Business Model Canvas

Physician groups, health systems, and clinics coordinate care and referrals into Walgreens’ network of over 9,000 US pharmacies, enabling e-prescribing workflows that Surescripts reported reached about 86% of prescriptions in 2023, streamlining dispensing and counseling. Co-located clinics and partnerships expand access points, while shared care plans support chronic disease management that drives roughly 90% of US healthcare spending.

Walgreens Boots Alliance (FY2024 net sales ~$132.5bn; ~1.6bn scripts) relies on pharma supply agreements, three major PBMs (~80% US scripts), health system referrals and logistics partners to secure inventory and cut stockouts ~15%; tech, telehealth and retail media partners drive omni‑channel revenue and personalization across ~9,000 US stores.

Curate front-of-store assortments across health, beauty, and convenience to reflect local demand and drive impulse purchases, leveraging Walgreens Boots Alliance scale across more than 8,200 stores. Execute pricing, promotions, and private-label strategy to improve margins and value perception, supporting fiscal 2024 net sales of about $139.5 billion. Manage planograms, seasonal resets, and inventory turns to reduce out-of-stocks and boost SKU productivity. Enhance in-store experience to lift traffic and basket size.

Verify, dispense and counsel on medications (9,000+ stores, FY2024 net sales ~$139.5B) under HIPAA and controlled-substance rules, managing refills, prior auths and MTM to improve outcomes. Provide vaccinations, testing and clinic care across >8,000 U.S. sites and expand telehealth/remote monitoring to reduce readmissions. Operate omnichannel commerce and myWalgreens loyalty (>70M members, 2024) to drive pickup, delivery, subscriptions and analytics-led retention.

Distribution centers, integrated IT systems and transportation assets underpin product availability across about 8,300 U.S. retail locations (2024), ensuring days-of-supply and refill continuity. DEA, FDA and state pharmacy licenses permit controlled-substance dispensing and regulatory compliance. Robust quality and compliance frameworks, including chain-of-custody and audit programs, mitigate risk. Long-term vendor relationships secure volume discounts and favorable procurement terms.

Walgreens Boots Alliance operates 9,000+ US pharmacy locations and 2,200+ Boots stores (2024), delivering dense retail access. myWalgreens exceeded 70M members and integrated eRX/EHR, distribution centers and vendor contracts support omnichannel supply. Licensed pharmacists (~312,000 US) plus clinic spaces, regulatory licenses and cybersecurity safeguard dispensing and PHI.

Generics, coupons, and payer alignment lower out-of-pocket costs—generics accounted for over 90% of U.S. prescriptions in 2024 (FDA), driving steep unit-cost reductions. Private-label health and beauty expand value choices and margin control. Membership and loyalty perks increase savings and repeat visits. Preventive services reduce downstream medical spend by catching issues early.

Walgreens Boots Alliance delivers convenient, trusted pharmacy care via ~8,200 U.S. locations (2024), same-day services, and omnichannel fulfillment, driving adherence and foot traffic. Clinical services, MTM and privacy controls reduce complications; generics >90% of U.S. scripts (2024) and payer alignment lower costs. FY2024 net sales 132.7B USD; ~60M loyalty members boost repeat visits.

Omnichannel support unifies in-store, phone, chat, and app interactions so customers access order status, refills, and appointments via self-serve tools; proactive notifications set expectations while integrated customer profiles expedite issue resolution. This model scales across Walgreens Boots Alliance’s network of over 8,000 U.S. stores (2024), driving continuity between digital and physical channels and reducing service friction.

Personalized pharmacist care and MTM across 8,200+ U.S. community pharmacies (2024) boost adherence and retention. myWalgreens surpassed 100M members in 2024, driving loyalty via targeted offers and omnichannel redemption. Partnerships (hundreds of VillageMD clinics) and 8,000+ stores unify digital, in‑store and B2B relationships to scale population health services.

Contactless drive-thru and curbside fulfillment at Walgreens speeds pickup for prescriptions and quick essentials while reducing in-store congestion and wait times; available across about 9,000 U.S. locations, these channels improve safety and throughput. They also enhance accessibility for mobility-limited customers by minimizing entry and queuing.

Omnichannel network—~8,000 Walgreens, >2,200 Boots, ~1,100 MinuteClinics and ~9,000 US locations—drives pharmacy, retail and clinical visits, supporting FY2024 net sales of 132.7 billion. Digital app, e‑prescribing and delivery/curbside extend reach and adherence while reducing errors. Wholesale and retail media (US retail media ~60 billion in 2024) monetize inventory and advertising.

Payers and PBMs steer pharmacy networks and reimbursement, collectively managing about 80% of U.S. prescription volume and thus determining Walgreens Boots Alliance's network access and negotiated rates. They evaluate cost, quality, and access metrics—cost per prescription, adherence rates, formulary placement—to set reimbursement and performance benchmarks. Contracts include adherence and clinical programs (MTM, prior authorization) that materially affect margin and patient volume.

Retail patients fill ≈900M prescriptions in 2024 and prioritize convenience, safety and pharmacist counsel. Health shoppers (MyWalgreens ≈90M; FY2024 sales $132.8B) seek wellness, beauty and value. Payers/PBMs (~80% RX control), providers and employers leverage ≈8,200 US stores and ~70M vaccinations annually for access and outcomes.

Leases, utilities, maintenance and security underpin Walgreens Boots Alliance’s footprint across roughly 8,000 retail locations, reflecting scale-driven occupancy costs that form a large portion of store-level SG&A; WBA reported FY2024 net sales of about $133.5 billion. Fixtures and equipment require ongoing upkeep and periodic replacement, while pharmacy clinic build-outs carry upfront capital and incremental operating expenses. Regulatory compliance and safety protocols further increase overhead and staffing costs.

Purchase of branded/generic drugs and pharmacy/wholesale drive largest costs; FY2024 net sales $133.5B with rebates/PBM chargebacks materially lowering net drug COGS. Labor (pharmacists mean $139,190; technicians $39,230) plus leases for ~8,000 US stores, logistics/cold-chain and IT/cybersecurity are major recurring expenses.

Front-of-store retail drives sales of health, beauty and convenience goods within Walgreens Boots Alliance, complementing FY2024 net sales of about $132.7 billion; private-label SKUs deliver higher margins and help traffic conversion, promotions and seasonal categories (holiday, cold/flu, back-to-school) lift average basket size, and cross-selling from pharmacy footfall materially increases front-of-store conversion and spend per visit.

Prescription dispensing (insurer/PBM/cash) is the core recurring revenue with generics ~90% of U.S. script volume, supporting stable pharmacy cash flows. Pharmacy services (vaccines, MTM, clinics, telehealth) and front-of-store retail raise margins and basket size; WBA FY2024 net sales $131.5B. Wholesale distribution and retail media monetize scale; US retail media ~62B (2023), data services lift margins.